You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is Which of the following drug is not used in MDB under RNTCP and explain in detail?
Regimen for MDR-TB This regimen comprises of 6 drugs Kanamycin, Levofloxacin, Ethionamide, Pyrazinamide, Ethambutol and Cycloserine during 6-9 months of the intensive phase and 4 drugs-Levovfloxacin, Ethionamide, Ethambutol and Cycloserine during the 18 months of the continuation phase. RNTCP regimen for MDR-TB : 6 (9) Km Lvx Eto Cs Z E/ 18 Lvx Eto Cs E* (Reserve/substitute drugs : PAS, Mfx, Cm) Special adjustments to the standard regimen for MDR-TB are as follows: In case of intolerance to Kanamycin, then Capreomycin (or PAS if injectable agent not feasible) is the available substitute drug. - In case of intolerance leading to discontinuation of other oral second-line drug, p-aminosalicylic acid (PAS) is the available substitute drug. - Baseline Kanamycin mono-resistance should lead to substitution of Kanamycin with Capreomycin. - Baseline Ofloxacin mono-resistance should lead to substitution of Levofloxacin with the combination of Moxifloxacin and PAS. - Baseline Ofloxacin and Kanamycin resistance (i.e. XDR-TB) should lead to declaration of outcome, referral to DR-TB Centre for pre-treatment evaluation for regimen for XDR-TB. Ref : Park 23rd edition Pgno : 191